Targeting Brain Disease in MPSII: Preclinical Evaluation of IDS-Loaded PLGA Nanoparticles

Targeting Brain Disease in MPSII: Preclinical Evaluation of IDS-Loaded PLGA Nanoparticles

Mucopolysaccharidosis type II (MPSII) is a lysosomal storage disorder due to the deficit of the enzyme iduronate 2-sulfatase (IDS), which leads to the accumulation of glycosaminoglycans in most organ-systems, including the brain, and resulting in neurological involvement in about two-thirds of the p...

Full description

Bibliographic Details
Main Authors: Laura Rigon, Marika Salvalaio, Francesca Pederzoli, Elisa Legnini, Jason Thomas Duskey, Francesca D’Avanzo, Concetta De Filippis, Barbara Ruozi, Oriano Marin, Maria Angela Vandelli, Ilaria Ottonelli, Maurizio Scarpa, Giovanni Tosi, Rosella Tomanin
Format: Article
Language:English
Published: MDPI AG 2019-04-01
Series:International Journal of Molecular Sciences
Subjects:
lysosomal storage disorders
mucopolysaccharidosis
Hunter syndrome
MPS II
enzyme replacement therapy
nanoparticles
PLGA
blood-brain barrier
central nervous system
brain targeting
Online Access:https://www.mdpi.com/1422-0067/20/8/2014

Internet

https://www.mdpi.com/1422-0067/20/8/2014

Similar Items